Is TCRT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Velaris and the pulmonary hypertension pipeline, with revenue at Essentially none (about $3,000 trailing twelve months); no product revenue. The bear case rests on the risks remain severe, though their nature has shifted. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The risks remain severe, though their nature has shifted. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Velaris and the pulmonary hypertension pipeline. The forward story now rests mainly on the Velaris programs.

The risks remain severe, though their nature has shifted. Until October 2026 Alaunos was a pre-revenue company with about $124,000 of cash at June 30, 2026, going-concern doubt and an April 2026 Nasdaq deficiency notice for failing the minimum stockholders' equity requirement; the Velaris acquisition and the roughly $350 million Fairmount-led financing are meant to fix that, but conversion of the preferred stock still needs a stockholder vote and the listing status should be confirmed. The new pipeline is early, with VLR199 proof-of-concept data not expected until 2028, and pulmonary hypertension is a field where Merck (whose Winrevair is an approved activin-signaling inhibitor) and other well-funded companies are active. Dilution is extreme: the as-converted share count of about 358.6 million dwarfs the pre-deal base, and control of the board passes to Fairmount designees. The stock is thinly traded and extremely volatile (it more than doubled in a month around the deal), and ALN1003's future was not addressed. There is a real possibility that shareholders lose most or all of their investment.

Alaunos Therapeutics, formerly Ziopharm Oncology, spent years as a clinical-stage cancer cell-therapy company developing T-cell receptor (TCR-T) therapies for solid tumors.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Velaris and the pulmonary hypertension pipeline) stalling in the reported numbers rather than in the narrative, the risk above (the risks remain severe, though their nature has shifted) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals and risk tolerance, and this is not investment advice, but the risk is extreme. Until October 2026 Alaunos was a pre-revenue company with almost no cash, a going-concern warning and a Nasdaq deficiency notice. The Velaris acquisition and a roughly $350 million Fairmount-led financing give it a funded pulmonary hypertension pipeline with runway into 2029, but they also dilute existing holders massively (about 358.6 million shares as-converted) and hand board control to Fairmount designees. The first key clinical data are not expected until 2028. Walnut is not an investment adviser.

As of October 2026 Alaunos still traded on Nasdaq under the ticker TCRT, and the Velaris announcement did not mention a name or ticker change. In April 2026 it received a notice that it no longer met the minimum stockholders' equity requirement under Listing Rule 5550(b)(1); the roughly $350 million private placement should address equity once completed, but listing status can change, so confirm the current situation before assuming the stock remains on Nasdaq.

Alaunos, formerly Ziopharm Oncology, was a cancer cell-therapy company that wound down its clinical study in 2023 and then pivoted to a preclinical obesity program centered on ALN1003. On October 13, 2026 it acquired Velaris Therapeutics, so its main focus is now pulmonary arterial hypertension and secondary pulmonary hypertension, led by VLR199, an ActRIIA-Fc ligand trap. It has no approved products and no product revenue.